Tokyo, Jan. 7 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000060271) titled 'Molecular subtyping of autism spectrum disorder using blood DNA methylation' on Jan. 6.
Study Type:
Observational
Primary Sponsor:
Institute - National Center of Neurology and Psychiatry
Condition:
Condition - Autism spectrum disorder
Classification by malignancy - Others
Genomic information - YES
Objective:
Narrative objectives1 - The objective of this study is to identify molecular subtypes of autism spectrum disorder using blood DNA methylation analysis and to characterize their biological features.
Basic objectives2 - Others
Eligibility:
Age-lower limit - 4
years-old
=
Gender - Male and Female
Key inclusion criteria - Individuals aged 4-18 years with autism spectrum disorder and controls included in the Simons Simplex Collection within the NIMH Data Archive, for whom blood DNA methylation data and relevant clinical information are available.
Key exclusion criteria - Individuals lacking blood DNA methylation data or essential clinical information in the database.
Target Size - 968
Recruitment Status:
Recruitment status - No longer recruiting
Date of protocol fixation - 2024 Year 04 Month 03 Day
Date of IRB - 2024 Year 04 Month 04 Day
Anticipated trial start date - 2024 Year 04 Month 04 Day
Last follow-up date - 2027 Year 03 Month 30 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000068942
Disclaimer: Curated by HT Syndication.
